The effect of thymoquinone on infantile spasm

Evaluation of the effect of thymoquinone in the treatment of infants with infantile refractory spasm

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200131046317N2

Enrollment

Registered

2021-04-15

Start date

2021-04-21

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infantile refractory spasm. Other specified disorders of nervous system in diseases classified elsewhere

Interventions

Intervention 1: Control group: Because no two patients with drug-resistant infantile spasm (in terms of underlying causes of disease, inheritance of disease, socioeconomic status and parental care a

Eligibility

Sex/Gender

All

Age

4 Months to 18 Months

Inclusion criteria

Inclusion criteria: Infants who, despite receiving at least 5 days of injectable corticotropin with at least one other appropriate drug for the treatment of infantile spasm, have at least 3 seizures per week as spasms or myoclonic Parental satisfaction

Exclusion criteria

Exclusion criteria: having liver or kidney disease. neurodegenerative disease.

Design outcomes

Primary

Measure	Time frame
Seizures numbers. Timepoint: At the beginning of the study and weekly for 3 weeks while taking thymoquinone. Method of measurement: Based on parents' reports.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactJavad Akhondian

Mashhad University of Medical Sciences

akhondianj@mums.ac.ir+98 51 3801 2496

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026